The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
There was a video on the medusa webpage walking you through administration of the test.
It also had photographs of packaging.
This has now been taken down.
Interesting.
HANG ON
To quote from the Description section of https://medusa19.com/medusa-19-life-science-rapid-saliva-test/
The RSPT is a colloidal gold immunochromatography test kit and detects the patients immune response to the virus using a patented buffer solution. This unique buffer can conserve proteins present in saliva which are produced by the body to the presence of the COVID-19 virus.
The lateral flow strip has lines to show whether you have the IgG and IgM antibodies to Covid-19 viral infection in your saliva. The reagents form lines, much in the same way as a pregnancy test, to reveal whether you are positive or negative for the Covid-19 antibodies.
Ignore...
Use this website as commented below https://medusa19.com/new-homepage/
It looks like there are two tests - one of which sounds like the MIT / 3M test??
Page is badly formatted so looks like it shouldn't be live...
Yeah infor25, I was thinking the same. I’d much rather see something like 80%/99.9% tbh. 95% specificity is not ideal for population screening. If 5% of people without the virus get a positive and have to isolate awaiting PCR confirmation, it doesn’t get us out of this chaos IMO. At 0.05% prevalence that means a positive result = about 1% chance you actually have the virus. A waste of time for track and trace to act on the LFT results if only 1/100 positive results are true. You want a rapid result, not a rapid ‘maybe’.
I don’t want to launch another argument about sensitivity/ specificity, as that discussion’s been done to death here. But I agree with you. Kind of hoping these are just holding numbers to test a webpage layout.
Omg...I would encourage everyone to look at it via phone... Looks like the phone version is nearly done and has MUCH more info vs desktop version.
https://medusa19.com/delivery/
Delivery
Business Orders
Currently, we deliver to businesses in the UK only.
We will be adding USA and European destinations soon.
Other international destinations will also be added later.
If you have a specific requirement for a non-supported destination, please contact our customer services team to see if we can accommodate your requirements.
Accuracy is sum of true positives plus true negatives divided by number of tests. Completely meaningless for a disease where the prevalence (percentage of people who have it is low) as in the case of covid19 (0.05% 2 weeks ago in England and Wales, ttps://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19roundup/2020-03-26).
You wouldn’t bother giving a web developer anything even close to sensitive information, real or otherwise. You’d use “Loren Ipsum” - standard practice.
Agreed. Doesn’t look like holding text.
Having looked at the pictures, it does look very odd, like two different tests. But IT HAS to be our test.
No chance. You’d lose your job instantly.
Nothing stopping medusa licenseing the test to increase production on there own, avcta will get paid regardless due to those magic affirmers.
I would argue it’s unlikely to be holding text. Possible, but unlikely. Having worked in that role or close to that role for 15+ years, it’s just too specific. It looks like a first draft accidentally run through whatever CMS they are running.
Seem to have a 3rd website too http://medusa19lifesciences.com/
Baffyman, well of course I know that... I implied in conjunction with Avacta through knowledge exchange (as stated in my post for those with a keen eye for detail).
Just had a mooch about and there are definitely two sites. Try this link instead https://medusa19.com/new-homepage/
It shows a shop, payment gateway and also an account and shopping cart. Think someone's dropped a proper boll**ck!!
vrmnd,
They can't produce their own affimer test, as AVCT have the patent for affimer use.
Going to be an accountancy reason to create another company surely...
The whole thing stinks.
I wish it was true but can’t see it.
Someone behind a computer playing pranks.
testing a new site and they forgot to switch something off, as mentioned above. None of this has been approved, and I suspect it's holding text. Bet someone gets a telling off.
I couldn't see the page for ages which kinda points to traffic split between real and test site.
I agree. I doubt the web developer was given this information. It's placeholder data to illustrate how it will be presented.
Maybe nothing but one of the links is titled "Prelaunch news" (https://medusa19.com/prelaunch-news/) Maybe as suggested someone jumping the gun or maybe just testing layout (in a live version seems a bit amateur). Bit of a F up if you ask me but looking forward to Monday
Yes but could M-19 LS be producing their own affimer-based test? AS keeps saying more partners needed to scale up production. Cytiva developed a test with Avacta, now they are share the knowledge with other companies (BBI...) to be able to produce more. But no idea what M-19 LS is meant to be since it just popped up.
Something is going on for sure. As a LTH, I‘m excited about next week (something I tell myself every Friday dreading the week-end wait)
Suspect those figures are just made up by the website developer and placeholders for the real info. This info is just too commercially "sensitive" to be dropped like that. In fact AL has said that himself - so would definitely be surprised if these are the real figures.
Medusa lifescience was incorporated 22 days ago. Is that time to come up with a saliva test? I think not. Maybe just rebranding Avacta who knows wh?